Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
NCT03432741 · Mayo Clinic · PHASE1 · terminated · last registry update 2025-05-26 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “funding - sponsor filing Chapter 11 bankruptcy” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody + Bevacizumab (NCT03280563)
- 2025-05-16Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Romidepsin + Abraxane (NCT01938833)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision